The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.
Real-time index price for TSX Composite Index (TXCX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...